Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Hong‐Shuai Li"'
Autor:
Ming‐Yi Zhang, Du He, Yi Zhang, Ke Cheng, Hong‐Shuai Li, Yu‐Wen Zhou, Qiong‐Xian Long, Rui‐Zhi Liu, Ji‐Yan Liu
Publikováno v:
MedComm, Vol 5, Iss 7, Pp n/a-n/a (2024)
Abstract This study aimed to identify the role of chromothripsis as a novel biomarker in the prognosis and differentiation diagnosis of pancreatic neuroendocrine neoplasms (pNENs). We conducted next‐generation gene sequencing in a cohort of 30 pati
Externí odkaz:
https://doaj.org/article/df25d9b76ec047b0a23daf8177770b40
Autor:
Wen-Jun Meng, Jia-Min Guo, Li Huang, Yao-Yu Zhang, Yue-Ting Zhu, Lian-Sha Tang, Jia-Ling Wang, Hong-Shuai Li, Ji-Yan Liu
Publikováno v:
Bioengineering, Vol 11, Iss 9, p 893 (2024)
Anoikis is a distinct type of programmed cell death and a unique mechanism for tumor progress. However, its exact function in gastric cancer (GC) remains unknown. This study aims to investigate the function of anoikis-related lncRNA (ar-lncRNA) in th
Externí odkaz:
https://doaj.org/article/50635a64c07d477c9f5ebb73268ff8f5
Influence of PD‐L1 expression on the efficacy of EGFR‐TKIs in EGFR‐mutant non‐small cell lung cancer
Autor:
Si‐Yu Lei, Hai‐Yan Xu, Hong‐Shuai Li, Ya‐Ning Yang, Fei Xu, Jun‐Ling Li, Zhi‐Jie Wang, Pu‐Yuan Xing, Xue‐Zhi Hao, Yan Wang
Publikováno v:
Thoracic Cancer, Vol 14, Iss 24, Pp 2327-2337 (2023)
Abstract Background Evidence on the influence of programmed death‐ligand 1 (PD‐L1) expression on the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) in EGFR‐mutant non‐small cell lung cancer (NSCLC) patie
Externí odkaz:
https://doaj.org/article/d67942b0ba6648a7aa30f1025dd0cd46
Publikováno v:
Thoracic Cancer, Vol 14, Iss 15, Pp 1368-1382 (2023)
Abstract Objective Advanced lung cancers carrying Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation remain a group that lacks effective treatments. Receptor activator of nuclear factorκB ligand (RANKL) has been demonstrated to drive maligna
Externí odkaz:
https://doaj.org/article/f2a8e2611a084fa7a22bbfd6bf1d9189
Publikováno v:
Cancer Medicine, Vol 11, Iss 4, Pp 1026-1036 (2022)
Abstract Objective Dacomitinib has been approved for the first‐line treatment of non‐small cell lung cancer (NSCLC) carrying classical epidermal growth factor receptor (EGFR) mutations; however, real‐world data on its later‐line application a
Externí odkaz:
https://doaj.org/article/7f436c831a2346e99efabc8c742cae23
Autor:
Hong-Shuai Li, Si-Yu Lei, Jun-Ling Li, Pu-Yuan Xing, Xue-Zhi Hao, Fei Xu, Hai-Yan Xu, Yan Wang
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
BackgroundSynergistic anti-tumor effects were observed in vivo and in vitro when immune checkpoint inhibitors (ICIs) were combined with denosumab. However, the clinical benefit and safety of this synergy have not been adequately evaluated in non-smal
Externí odkaz:
https://doaj.org/article/5b820fc5acdb4b2cb14e1c5c76b6ece7
Autor:
Hong-Shuai Li, Guang-Jian Yang, Yi Cai, Jun-Ling Li, Hai-Yan Xu, Tao Zhang, Li-Qiang Zhou, Yu-Ying Wang, Jin-Liang Wang, Xing-Sheng Hu, Xiang Yan, Yan Wang
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Objective: Dacomitinib has been approved for non-small-cell lung cancer (NSCLC) patients harboring classical epidermal growth factor receptor (EGFR) mutations; however, clinical evidence of its activity on major uncommon EGFR mutations is currently l
Externí odkaz:
https://doaj.org/article/a0304755a1dc4eaf9b7018977d22936b
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
The acquired EGFR C797X mutation has been identified as the most notable resistance to osimertinib, and novel secondary mutations of EGFR L718 and L792 residues have also been demonstrated to confer osimertinib resistance, making the choice of medica
Externí odkaz:
https://doaj.org/article/1c886ee1ea4b4504ab20481da8aac696
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Human epidermal growth factor receptor 2 (HER2) has been verified as a valuable biomarker and treatment target in metastatic colorectal cancer (mCRC). Pyrotinib, a novel irreversible HER2/epidermal growth factor receptor (EGFR) dual tyrosine kinase i
Externí odkaz:
https://doaj.org/article/61a5ea8fabb447f8b9ddcc4fdde4c1c1
Publikováno v:
Thoracic Cancer. 14:1368-1382
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cae3b29a3aebe0e1d9615d1f13dcee4a
https://doi.org/10.1111/1759-7714.14882
https://doi.org/10.1111/1759-7714.14882